Michael P. Woodward Supervisory Patent Examiner Art Unit 1631 (703) 308-4028 SNiPpetS & Bytes

Slides:



Advertisements
Similar presentations
Patent Prosecution June 2013 June 13, 2013.
Advertisements

Technology Center 1600 Training on Writing Rejections Under 35 U.S.C. § 103.
Combinatorial Technology Supervisory Patent Examiner
Patenting Antisense Oligonucleotides and Methods
Michael P. Woodward Supervisory Patent Examiner, Art Unit 1631 (703) Bioinformatics & §101
35 U.S.C. 112, 6th Paragraph Long V. Le SPE, AU 1641 (703)
Software: To Patent or Not? Jeffrey P. Kushan Powell, Goldstein, Frazer & Murphy, LLP.
Filing for a United States Patent “Helpful Hints” U.S. Patent and Trademark Office.
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
Utility and Written Description Steve Kunin Deputy Commissioner for Patent Examination Policy Esther Kepplinger Deputy Commissioner for Patent Operations.
Recent Cases on Patentable Subject Matter and Patent Exhaustion Mojdeh Bahar, J.D., M.A. Chief, Cancer Branch Office of Technology Transfer National Institutes.
1 Homology Language Brian R. Stanton Quality Assurance Specialist Technology Center 1600 U.S. Patent and Trademark Office (703)
1 Bioinformatics Practice Considerations October 20, 2011 Ling Zhong, Ph.D.
UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the “Notes” Tab. Claim Interpretation: Broadest Reasonable.
1 Rule 132 Declarations and Unexpected Results Richard E. Schafer Administrative Patent Judge Board of Patent Appeals and Interferences.
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
Invention Spotting – Identifying Patentable Inventions Martin Vinsome June 2012.
Memorandum - 35 U.S.C. 112, Second and Sixth Paragraphs Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark.
Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
Claim Interpretation By: Michael A. Leonard II and Jared T. Olson.
“REACH-THROUGH CLAIMS”
1 Biotechnology Partnership Meeting April 17, 2001 James Martinell Senior Level Examiner Technology Center 1600.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
1 Single Nucleotide Polymorphisms (SNP) Gary Jones SPE, Technology Center 1600 (703)
Restriction Practice for Genus Claims Species Claims Linking Claims and Markush Claims Julie Burke QAS/PM TC1600.
In re Bilski (Fed Cir. 2008) Patentable subject matter In re Bilski (Fed Cir. 2008) Patentable subject matter December 2, 2008 John King Ron Schoenbaum.
EVALUATING SUBJECT MATTER ELIGIBILITY UNDER 35 U. S. C
Patents Copyright © Jeffrey Pittman. Pittman - Cyberlaw & E- Commerce 2 Legal Framework of Patents The U.S. Constitution, Article 1, Section 8:
Determining Obviousness under 35 USC 103 in view of KSR International Co. v. Teleflex TC3600 Business Methods January 2008.
Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Biotechnology/Chemical/Pharmaceutical Customer Partnership Topic: Examining Issues When.
1 TC 1600 Subject Matter Eligibility Under 35 USC § 101 Andrew Wang SPE 1631 (571)
Patent Quality Assurance Program. 2 Office of Patent Quality Assurance (OPQA) Deputy Commissioner for Patent Operations Office of Patent Quality Assurance.
Patent Overview by Jeff Woller. Why have Patents? Patents make some people rich – but, does that seem like something the government should protect? Do.
Issues in Patenting Proteins Jon P Weber, SPE 1657.
Patent Applications Overlapping the Biotechnology and Mechanical Arts THOMAS BARRETT
Examiner Guidelines After Alice Corp. August 21, 2014 How Much “More” is “Significantly More”?
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
35 USC 101 Update Business Methods Partnership Meeting, Spring 2008 by Robert Weinhardt Business Practice Specialist, Technology Center 3600
1 ANTICIPATION BY INHERENCY IN PRIOR ART James O. Wilson Supervisory Patent Examiner Technology Center 1600 USPTO (571)
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
1 John Calvert Supervisory Patent Examiner
U.S. Patent and Trademark Office Technology Center 1600 Michael P. Woodward Unity of Invention: Biotech Examples.
1 Restriction Practice Updates Julie Burke TC1600 Quality Assurance Specialist
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
Patentability of Reach-Through Claims Brian R. Stanton Practice Specialist Technology Center 1600 (703)
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
Overview Validity of patent hinges on novelty, utility, and non-obviousness Utility generally not an issue Pre-suit investigation focuses on infringement,
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
Pilot Concerning Public Submission of Peer Reviewed Prior Art Jack Harvey Director, TC 2100.
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
How to Claim your Biotech- Based Invention Deborah Reynolds Detailee, TCPS
INTERIM GUIDELINES FOR PATENT SUBJECT MATTER ELIGIBILITY ARDIN MARSCHEL SPE AU 1631 (571)
1 Enablement Issues in Pharmaceutical Claims Joseph K. M c Kane Supervisory Patent Examiner Art Unit Ardin Marschel Supervisory Patent.
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
1 Examination Guidelines for Business Method Invention 24. Jan Young-tae Son( 孫永泰, Electronic Commerce Examination Team Korean.
Alexandria, Virginia July 21, 2014
Preparing a Patent Application
Processes Which Employ Non-Obvious Products
Of Counsel Polsinelli, LLP
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
Comparing subject matter eligibility in us and eu
Preparing a Patent Application
Examination Practice in Applications Presenting “Reach-Through Claims”
Patentable Subject Matter in Korea
Presentation transcript:

Michael P. Woodward Supervisory Patent Examiner Art Unit 1631 (703) SNiPpetS & Bytes

What is Bioinformatics? Computational Biology: Use of computational methods to solve biological problems Involves storage, retrieval and analysis of biological data Will aid in gene discovery, molecular modeling, mutagenesis

Bioinformatics Involves methods reciting significant data processing steps directed to inventions in areas such as gene sequencing, nucleic acid hybridization, protein structure prediction, X-ray crystallography, pharmacology, receptor-ligand modeling, and immunology.

Bioinformatics: Challenges For USPTO Creating appropriate classification systems for bioinformatics inventions - establishing definitions of what these applications comprise Processing and examination of the inventions and the voluminous data - implementing search infrastructure for analysis of large data sets Searching the bioinformatics prior art Staffing and training for examination of bioinformatics Legal issues pertaining to bioinformatics

Bioinformatics: Prior Art Searching Developing collections of bioinformatics-related patents to serve as initial search resources: –Searching publications of assignees pursuing this technology –Patents currently in Class 702/subclasses which are directed to bioinformatics – Sequence alignments – 3D modeling – Motif/pattern searching – DNA on a chip technology

Bioinformatics Art Unit 1631 Inventory of 275 "informatics" patent applications pending; 123 filed after October 1, 2000 Projection: Over 300 applications this year Coordinates with TC 2100 and TC 2600(computer- related inventions) with regard to examination practice to maintain consistency Encourage interviews so both parties can better understand the invention and how it should be claimed

Bioinformatics: Examiner Training Specialized training with respect to 35 USC §112, first paragraph, including ESTs, 35 USC §101 with regard to biotechnology and computer based inventions and 35 USC §112, sixth paragraph. How to search the prior art for algorithms and other mathematical issues Currently available bioinformatics software packages Seminars and interactive sessions with representatives from firms and universities actively involved in bioinformatics

Case Law Impacting Bioinformatics State Street Bank & Trust Co. v. Signature Financial Group Inc. AT&T Corporation v. Excel Communications, Inc. –Are part of a favorable legal climate for private research and development of bioinformatics –Provide a framework for patent protection for inventions involving mathematical algorithms and business methods, e.g., bioinformatics

Case Law Impacting Bioinformatics In re Lowry, 32 F.3d 1579, 32 USPQ2d 1031 (Fed. Cir. 1994) (claim to data structure stored on a computer readable medium and that increases computer efficiency held statutory subject matter) In re Warmerdam, 33 F.3d 1354, 31 USPQ2d 1754 (Fed. Cir. 1994) (claim to data structure per se held nonstatutory subject matter where data structure did not cause functional change in computer)

Case Law Impacting Bioinformatics In re Gulack, 703 F.2d 1381, 1385, 217 USPQ 401, 404 (Fed. Cir. 1983) (when descriptive material is not functionally related to the substrate, the descriptive material will not distinguish the invention from the prior art in terms of patentability).

Non-functional Descriptive Material Mere arrangements or compilations of facts or data, stored so as to be read or outputted by a computer without creating any functional interrelationship, either as part of the stored data or as part of the computing processes performed by the computer.

A Common Situation A process that differs from the prior art only with respect to nonfunctional descriptive material that cannot alter how the process steps are to be performed to achieve the utility of the invention.

Obviousness and Non-Functional Descriptive Material If the difference between the prior art and the claimed invention is limited to descriptive material stored on or employed by a machine, Office personnel must determine whether the descriptive material is functional descriptive material or nonfunctional descriptive material. Functional descriptive material is a limitation in the claim and must be considered and addressed in assessing patentability under 35 U.S.C. 103.

Obviousness and Non-Functional Descriptive Material (Cont.) Thus, a rejection of the claim as a whole under 35 U.S.C. 103 is inappropriate unless the functional descriptive material would have been suggested by the prior art. Nonfunctional descriptive material cannot render nonobvious an invention that would have otherwise been obvious.

A Virtual Life Example A method of determining the most hydrophilic peptide in a polypeptide comprising a sequence of at least six amino acid residues which method comprises: (a) Determining the amino acid sequence of said polypeptide; (b) Assigning relative hydrophilicity values to each sequenced amino acid; (c) Determining the repetitive local average of hydrophilicity values on the basis of said assigned values of each residue of at least six amino acids sequentially along said polypeptide; (d) Comparing said repetitive local averages and selecting the peptide of at least six amino acid residues corresponding to the greatest local average hydrophilicity.

Pending Claim 1. A method of determining the most hydrophilic peptide in a polypeptide comprising a sequence of at least six amino acid residues which method comprises: (a) Inputting SEQ ID NO:2; (b) Assigning relative hydrophilicity values to each sequenced amino acid; (c) Determining the repetitive local average of hydrophilicity values on the basis of said assigned values of each residue of at least six amino acids sequentially along said polypeptide; (d) Comparing said repetitive local averages and determining the peptide of at least six amino acid residues corresponding to the greatest local average hydrophilicity.

Conclusion Because the specifically recited SEQ ID NO: 2 is mere data and does not alter the actual process steps the claim would be rejected as obvious over the reference disclosure.

Tips for Bioinformatics Applicants Applicants should be increasingly aware of overlapping biotech and computer technologies To the extent that an invention overlaps into the computer arts, biotech attorney should become familiar with the Examination Guidelines for Computer-Related Inventions Consult MPEP for information on the submission of computer programs and/or flow charts.

Tips for Bioinformatics Applicants Avoid claims to a computer readable media with sequence data on it. These claims are drawn to non statutory descriptive matter. However, a claim to a software program on a disk may be statutory.

Tips for Bioinformatics Applicants Take care to distinguish clearly between manipulation of molecules and sequence information, e.g., software that deletes flanking vector sequences from insert sequences after sequencing a clone. Do not phrase the claim to recite deletion of nucleic acids from the vector nucleic acid, if you really intend to refer to sequence data or information.

Tips for Bioinformatics Applicants Come in for Interviews: Clarity of and support for claim language has been a central issue. Claims tend to be extremely broad and actual embodiments are frequently difficult to understand which has led to confusion. Both applicants and their representatives have been wonderfully cooperative in having interviews and explaining their inventions.

Tips for Bioinformatics Applicants Consider both the biotechnology aspects and the computer software aspects of the invention; make sure the disclosure is ample for both. Trap: citing an example of a computer program which you assert can be adapted to perform the computer aspects of the invention. During prosecution you may become aware of the fine points of the computer components which may render the claims patentable but the specification may provide inadequate support for a specific computer.

Tips for Bioinformatics Applicants Assert a practical utility and disclose how it is realized in the specification. Submit an IDS, especially foreign patents and NPL to assist examiner. Provide the most relevant prior art in usable form and information on the state of the art. Disclose and claim clearly what is the real invention.

Tips for Bioinformatics Applicants Provide more information regarding the significance of art recognized terminology used in the patent application. Define such terms in the specification. –These terms may be hard to search. –It may not be clear how broadly these terms are being applied. –Be especially clear as to how the invention differs from the prior art as many statistical techniques and mathematical elements are prior art but are difficult to find in searches.

Tips for Bioinformatics Applicants Pay attention to the sequence rules, especially formal matters pertaining to references to sequences

Definition of SNP Single Nucleotide Polymorphism - A single base difference in a DNA sequence among individuals.

Issues/Prior Art Would a single base difference over the prior art have been obvious? Absent a teaching, suggestion, or motivation to modify the nucleic acid sequence at a particular location found in the prior art or in the knowledge generally available to one skilled in the art, such a difference would not have been obvious.

SNPs and Utility A specification setting forth a specific, substantial and credible utility for a SNP would satisfy the utility requirement.

William “Gary” Jones Supervisory Patent Examiner Art Unit 1655 (703) SNiPpetS

Michael P. Woodward Supervisory Patent Examiner Art Unit 1631 (703) SNiPpetS & Bytes